Literature DB >> 9083028

First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells.

V Wu1, M Yang, J A McRoberts, J Ren, R Seensalu, N Zeng, M Dagrag, M Birnbaumer, J H Walsh.   

Abstract

Cholecystokinin (CCK)-A and CCK-B receptors are highly homologous members of the seven transmembrane domain G-protein-coupled receptor superfamily. Genes of both receptors contain five exons and share a similar exon-intron organization. To determine the structural basis of CCK-A receptor (CCK-AR) functionally coupled to Gs, a series of chimeric mutants were constructed by replacing exons of human CCK-B receptor (CCK-BR), from the second to the fifth (last) exon, with human CCK-AR counterparts. Binding and signal transduction properties of wild-type and chimeric receptors were examined in stably transfected HEK-293 cells. Chimeric receptors that maintained high affinity binding to CCK exhibited dose-dependent increases in intracellular calcium mobilization similar to both wild-type receptors. However, only the wild-type CCK-AR and chimeric mutants containing the second exon of CCK-AR were able to mediate significantly greater increases in intracellular cAMP content and adenylyl cyclase activity compared with wild-type CCK-BR. A CCK-BR mutant was further constructed by replacing five amino acids, Gly-Leu-Ser-Arg-(Arg)-Leu, in the first intracellular loop with the corresponding five CCK-AR specific amino acids, Ile-Arg-Asn-Lys-(Arg)-Met. The resultant receptor maintained high affinity binding to both CCK and gastrin and dose-dependent calcium responses similar to wild-type CCK-BR. However, this first intracellular loop mutant also gained positive cAMP responses to both sulfated CCK-8 and gastrin-17 with EC50 values of 8.5 +/- 1 nM and 23 +/- 7 nM, respectively. These data suggest that the first intracellular loop of CCK-AR is essential for coupling to Gs and activation of adenylyl cyclase signal transduction cascade.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083028     DOI: 10.1074/jbc.272.14.9037

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Differential sensitivity of types 1 and 2 cholecystokinin receptors to membrane cholesterol.

Authors:  Ross M Potter; Kaleeckal G Harikumar; S Vincent Wu; Laurence J Miller
Journal:  J Lipid Res       Date:  2011-10-21       Impact factor: 5.922

2.  Differential determinants for coupling of distinct G proteins with the class B secretin receptor.

Authors:  Gene L Garcia; Maoqing Dong; Laurence J Miller
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

3.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

4.  Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells.

Authors:  Boris Tchernychev; Yong Ren; Pallavi Sachdev; Jay M Janz; Lynn Haggis; Adam O'Shea; Ed McBride; Richard Looby; Qing Deng; Thomas McMurry; Manija A Kazmi; Thomas P Sakmar; Stephen Hunt; Kenneth E Carlson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-07       Impact factor: 11.205

Review 5.  Involvement of endogenous CCK and CCK1 receptors in colonic motor function.

Authors:  Gábor Varga; András Bálint; Beáta Burghardt; Massimo D'Amato
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

6.  Evidence of the importance of the first intracellular loop of prokineticin receptor 2 in receptor function.

Authors:  Ana Paula Abreu; Sekoni D Noel; Shuyun Xu; Rona S Carroll; Ana Claudia Latronico; Ursula B Kaiser
Journal:  Mol Endocrinol       Date:  2012-06-28

Review 7.  Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.

Authors:  Erin E Cawston; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

8.  Functional characterization of a new human melanocortin-4 receptor homozygous mutation (N72K) that is associated with early-onset obesity.

Authors:  Patric J D Delhanty; Elise Bouw; Martin Huisman; Resie M L Vervenne; Axel P N Themmen; Aart Jan van der Lely; Erica L T van den Akker
Journal:  Mol Biol Rep       Date:  2014-08-28       Impact factor: 2.316

9.  Mechanisms of action of CCK to activate central vagal afferent terminals.

Authors:  Richard C Rogers; Gerlinda E Hermann
Journal:  Peptides       Date:  2008-07-04       Impact factor: 3.750

Review 10.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.